Engineered Extracellular Vesicle-Based Nanoformulations That Coordinate Neuroinflammation and Immune Homeostasis, Enhancing Parkinson's Disease Therapy

• Published in: ACS nano 2024-08, Vol.18 (34), p.23014
• Main Authors: Zhang, Chuan, Shao, Wei, Yuan, Hao, Xiao, Ru, Zhang, Yaru, Wei, Chaoqi, Ni, Xinyi, He, Ning, Chen, Guangliang, Gui, Shuangying, Cheng, Zhifei, Wang, Qi
• Format: Article
• Language: English
• Subjects: Animals; Drug Carriers - chemistry; Extracellular Vesicles - chemistry; Homeostasis - drug effects; Humans; Inflammation - drug therapy; Inflammation - immunology; Inflammation - pathology; Male; Mesenchymal Stem Cells - drug effects; Mice; Mice, Inbred C57BL; Microglia - drug effects; Microglia - metabolism; Nanoparticles - chemistry; Neuroinflammatory Diseases - drug therapy; Neuroinflammatory Diseases - immunology; Parkinson Disease - drug therapy; Parkinson Disease - immunology; Parkinson Disease - therapy
• ISSN: 1936-086X; 1936-086X
• DOI: 10.1021/acsnano.4c04674

Although conventional intervention to microglia can mitigate neuroinflammation in the short term, immune disorders by peripheral inflammatory cells can infiltrate continuously, resulting in an overactivated immune microenvironment of Parkinson's disease (PD). Here, we design engineered extracellular vesicle-based nanoformulations (EVNs) to address multiple factors for the management of PD. Specifically, EVN is developed by coating CCR2-enriched mesenchymal stem cell-derived extracellular vesicles (MSC EVs) onto a dihydrotanshinone I-loaded nanocarrier (MSeN-DT). The MSC EVs (the shell of EVN) can actively show homing to specific chemokines CCL2 in the substantia nigra, which enables them to block the infiltration of peripheral inflammatory cells. Interestingly, MSeN-DT (the core of EVN) can promote the Nrf2-GPX4 pathway for the suppression of the source of inflammation by inhibiting ferroptosis in microglia. In the PD model mice, a satisfactory therapeutic effect is achieved, with inhibition of peripheral inflammatory cell infiltration, precise regulation of inflammatory microglia in the substantia nigra, as well as promotion of behavioral improvement and repairing damaged neurons. In this way, the combinatorial code of alleviation of inflammation and modulation of immune homeostasis can reshape the immune microenvironment in PD, which bridges internal anti-inflammatory and external immunity. This finding reveals a comprehensive therapeutic paradigm for PD that breaks the vicious cycle of immune overactivation.